To the Editor We welcome the Viewpoint by Adamson1 on how regulatory agencies can improve the health of children through requirements and incentives for pediatric cancer medicines. This is done at the European Medicines Agency by the Pediatric Committee, which has overseen pediatric investigation plans (PIPs) since 2007.2 However, we do not share Dr Adamson’s views on 2 points.
Herold R, Saint-Raymond A, Norga K. Too Few Medicines for Children With Cancer. JAMA Pediatr. 2014;168(6):583. doi:10.1001/jamapediatrics.2014.15